A New Dawn for Glaucoma Treatment: The FLigHT Procedure
Glaucoma, a leading cause of irreversible blindness worldwide – affecting over 79 million people globally as of 2020, according too the World Health Institution – often progresses silently, damaging the optic nerve. Traditional treatments focus on lowering intraocular pressure (IOP), but many involve invasive surgery or ongoing medication. Now, a groundbreaking approach called flight – an acronym for “femtosecond laser image-guided high-precision trabeculotomy” – is offering a potentially transformative solution.
Beyond Traditional Surgery: precision Laser Intervention
The FLigHT procedure represents a paradigm shift in glaucoma management. Unlike conventional surgical methods, it doesn’t rely on incisions, implants, or physically altering the eye’s structure. Instead, it utilizes incredibly focused laser pulses to establish a microscopic pathway within the eye’s natural drainage system, the trabecular meshwork. This restored drainage facilitates fluid outflow, effectively reducing IOP.
What truly sets FLigHT apart is its non-invasive nature. Asz explains, “This is a procedural intervention, but it doesn’t feel like surgery. There’s no cutting, no need for stitches, and the patient experiences minimal discomfort.” The laser energy passes through the cornea without causing any sensation.
The Patient Experience: Rapid and Recovery-free
From the patient’s viewpoint, the procedure is remarkably straightforward. A specialized lens gently stabilizes the eye while the surgeon, guided by real-time imaging, precisely targets the treatment area. The laser then swiftly creates a drainage channel measuring just 500 microns in width and 200 microns in height – comparable in size to a speck of dust.
The benefits are immediate and compelling. Patients typically experience no pain, require no recovery period, and have no visible signs of treatment. remarkably,many report improved clarity of vision immediately following the procedure. Early results demonstrate sustained IOP reduction for up to four years, and the procedure can be safely repeated if necessary, as each session targets only a small segment of the drainage angle.
A Journey of Innovation: From LASIK to Glaucoma
the progress of FLigHT wasn’t an overnight success.It’s the culmination of decades of dedicated research and technological advancement. Initially, applying femtosecond lasers to glaucoma treatment proved challenging due to limitations in imaging and laser precision.This led Asz to pivot his focus, ultimately pioneering the laser technology that underpinned intralase, the frist femtosecond laser used in LASIK surgery. (In LASIK, the laser reshapes the cornea to correct refractive errors; in FLigHT, it creates a drainage channel to alleviate pressure.) His contributions were recognized in 2002 with the prestigious Berthold leibinger Innovation Prize,celebrating his breakthroughs in laser technology.
Returning to glaucoma research in 2017, Asz leveraged these advancements to finally realize the potential of femtosecond lasers for a minimally invasive IOP-lowering procedure. He emphasizes the importance of perseverance, stating, “This began in the mid-1990s. It’s 2025, and we’re finally reaching the finish line. It requires time, but unwavering belief is key.”
The FLigHT procedure offers a beacon of hope for the millions affected by glaucoma, promising a future where vision preservation is simpler, safer, and more effective.